Vaxart, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $27.2M | $39.2M | $104.2M | $72.4M | $39.7M | $20.9M | $15.2M | $4.9M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $33.8M | $29.4M | $45.2M | $75.9M | $49.7M | $30.7M | $22.7M | $15.1M |
| SG&A Expense | $6.6M | $4.6M | $3.7M | $4.3M | $4.6M | $5.1M | $4.0M | $4.3M |
| Operating Income | $-13.2M | $5.2M | $55.4M | $-7.8M | $-14.6M | $-14.9M | $-11.5M | $-14.5M |
| Operating Margin | -48.5% | 13.2% | 53.2% | -10.8% | -36.8% | -71.5% | -75.7% | -293.4% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-13.5M | $5.2M | $55.4M | $-8.1M | $-15.0M | $-15.5M | $-11.8M | $-14.1M |
| Income Tax Expense | $29.0K | $29.0K | $344.0K | $17.0K | $20.0K | $95.0K | $176.0K | $18.0K |
| Net Income | $-13.5M | $5.2M | $55.0M | $-8.1M | $-15.0M | $-15.6M | $-12.0M | $-14.1M |
| Net Margin | -49.6% | 13.2% | 52.8% | -11.2% | -37.7% | -74.7% | -78.9% | -285.4% |
| EPS (Basic) | $-0.06 | $0.02 | $0.25 | $-0.04 | $-0.07 | $-0.07 | $-0.04 | $-0.06 |
| EPS (Diluted) | — | $0.02 | — | — | — | $-0.07 | — | — |
| Shares Outstanding (Basic) | 242.2M | 240.6M | 230.3M | 228.9M | 228.4M | 227.9M | 202.1M | 227.5M |
| Shares Outstanding (Diluted) | 242.2M | 242.2M | 230.3M | 228.9M | 228.4M | 227.9M | 202.1M | 227.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |